<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53659">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01880931</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0239</org_study_id>
    <nct_id>NCT01880931</nct_id>
  </id_info>
  <brief_title>The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation in Normotensive and Hypertensive Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find out the effect site concentration of remifentanil for preventing QTc interval
      prolongation during intubation under propofol-remifentanil anesthesia in normotensive and
      hypertensive patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that anesthetic agents can influence the QTc. In addition, tracheal intubation
      during induction can stimulates sympathetic activity, which, as a results, prolong the QTc
      interval. Therefore, the aim of study is to find out the effect site concentration of
      remifentanil for preventing QTc interval prolongation during intubation under
      propofol-remifentanil anesthesia in normotensive and hypertensive patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The effect site concentration of remifentanil for preventing QTc interval prolongation</measure>
    <time_frame>2 min</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intubation, Intratracheal</condition>
  <arm_group>
    <arm_group_label>Normotensive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To find out the effect site concentration of remifentanil for preventing QTc prolongation &lt; 15 sec during intubation : Dixon's up-and-down method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To find out the effect site concentration of remifentanil for preventing QTc prolongation &lt; 15 sec during intubation : Dixon's up-and-down method</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The effect site concentration of remifentanil</description>
    <arm_group_label>Normotensive patients</arm_group_label>
    <arm_group_label>Hypertensive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 50 years ASA class I-II female who received surgery with endotracheal intubation

        Exclusion Criteria:

          -  emergency surgery electrocardiography abnormality diabetes mellitus end stage renal
             disease moderate to severe cardiac disease moderate to severe liver dysfunction
             systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg with no
             hypertension medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>So Yeon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>So Yeon Kim, MD, PhD</last_name>
    <phone>82-2-2227-4470</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Yeon Kim, MD, PhD</last_name>
      <phone>82-2-2227-4470</phone>
      <email>KIMSY326@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 25, 2013</lastchanged_date>
  <firstreceived_date>June 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>So Yeon Kim</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
